TP53 and myelodysplastic syndrome: Blast percentage and preceding cytotoxic therapy have been reported to be associated with prognosis in TP53-mutated MDS; however, we did not see any difference in prognosis between MDS with excess blasts and other MDS, or between de novo and therapy-related disease in our cohort [32,36].